Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-08-2018 | Review – Cancer Research

MicroRNAs in regulation of triple-negative breast cancer progression

Authors: Dominika Piasecka, Marcin Braun, Radzislaw Kordek, Rafal Sadej, Hanna Romanska

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2018

Abstract

Purpose

Dysregulation of miRNA profile has been associated with a broad spectrum of cellular processes underlying progression of various human malignancies. Increasing evidence suggests that specific microRNA clusters might be of clinical utility, especially in triple-negative breast carcinoma (TNBC), devoid of both predictive markers and potential therapeutic targets. Here we provide a comprehensive review of the existing data on microRNAs in TNBC, their molecular targets, a putative role in invasive progression with a particular emphasis on the epithelial-to-mesenchymal transition (EMT) and acquisition of stem-cell properties (CSC), regarded both as prerequisites for metastasis, and significance for therapy.

Methods

PubMed and Medline databases were systematically searched for the relevant literature. 121 articles have been selected and thoroughly analysed.

Results

Several miRNAs associated with EMT/CSC and invasion were identified as significantly (1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC. Dysregulation of miR-10b, miR-21, miR-29, miR-145, miR-200 family, miR-203, miR-221/222 was reported of prognostic value in TNBC patients.

Conclusion

Available data suggest that specific microRNA clusters might play an important role in biology of TNBC, understanding of which should assist disease prognostication and therapy.

Arpino G, Milano M, De Placido S (2015) Features of aggressive breast cancer. Breast 24:594–600. https://doi.org/10.1016/J.BREAST.2015.06.001 PubMedCrossRef

Avery-Kiejda KA, Mathe A, Scott RJ (2017) Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases. Genom Data 14:1–4. https://doi.org/10.1016/J.GDATA.2017.07.004 PubMedPubMedCentralCrossRef

Baroni S, Romero-Cordoba S, Plantamura I et al (2016) Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis 7:e2312–e2312. https://doi.org/10.1038/cddis.2016.224 PubMedPubMedCentralCrossRef

Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z, Demirel D (2014) miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J Breast Cancer 17(2):143–148. https://doi.org/10.4048/jbc.2014.17.2.143 PubMedPubMedCentralCrossRef

Bojmar L, Karlsson E, Ellegård S et al (2013) The role of MicroRNA-200 in progression of human colorectal and breast cancer. PLoS One 8:e84815. https://doi.org/10.1371/journal.pone.0084815 PubMedPubMedCentralCrossRef

Chang YY, Kuo WH, Hung JH et al (2015) Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer 14:36. https://doi.org/10.1186/s12943-015-0301-9 PubMedPubMedCentralCrossRef

Chao C-H, Chang C-C, Wu M-J et al (2014) MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 124:3093–3106. https://doi.org/10.1172/JCI73351 PubMedPubMedCentralCrossRef

Chen J, Tian W, Cai H et al (2012) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29:2527–2534. https://doi.org/10.1007/s12032-011-0117-4 PubMedCrossRef

Chen D, Dang B-L, Huang J et al (2015) MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. Oncotarget 6:32701–32712. https://doi.org/10.18632/oncotarget.4702 PubMedPubMedCentralCrossRef

Chen J, Shin VY, Siu MT et al (2016) miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer 16:887. https://doi.org/10.1186/s12885-016-2916-7 PubMedPubMedCentralCrossRef

Cohen EN, Gao H, Anfossi S et al (2015) Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells. PLoS One 10:1–18. https://doi.org/10.1371/journal.pone.0132710 CrossRef

Costa RLB, Gradishar WJ (2017) Triple-negative breast cancer: current practice and future directions. J Oncol Pract 13:301–303. https://doi.org/10.1200/JOP.2017.023333 PubMedCrossRef

D’Angelo RC, Ouzounova M, Davis A et al (2015) Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther 14:779–787. https://doi.org/10.1158/1535-7163.MCT-14-0228 PubMedPubMedCentralCrossRef

D’Ippolito E, Plantamura I, Bongiovanni L et al (2016) miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer. Cancer Res 76:5562–5572. https://doi.org/10.1158/0008-5472.CAN-16-0140 PubMedCrossRef

DeCastro AJ, Dunphy KA, Hutchinson J et al (2013) MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of ∆NP63α and promotes mesenchymal-to-epithelial transition. Cell Death Dis 4:e514. https://doi.org/10.1038/cddis.2013.37 PubMedPubMedCentralCrossRef

Dong G, Liang X, Wang D et al (2014) High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 31:57. https://doi.org/10.1007/s12032-014-0057-x PubMedCrossRef

Drago-Ferrante R, Pentimalli F, Carlisi D, De Blasio A, Saliba C, Baldacchino S, Degaetano J, Debono J, Caruana-Dingli G, Grech G, Scerri C, Tesoriere G, Giordano A, Vento R, Di Fiore R (2017) Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget 8(17):28939–28958. https://doi.org/10.18632/oncotarget.15960 PubMedPubMedCentralCrossRef

Eades G, Wolfson B, Zhang Y et al (2015) lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res 13:330–338. https://doi.org/10.1158/1541-7786.MCR-14-0251 PubMedCrossRef

Edmonds MD, Hurst DR, Vaidya KS et al (2009) Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J cancer 125:1778–1785. https://doi.org/10.1002/ijc.24616 PubMedPubMedCentralCrossRef

Eichelser C, Flesch-Janys D, Chang-Claude J et al (2013) Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59:1489–1496. https://doi.org/10.1373/clinchem.2013.205161 PubMedCrossRef

Erturk E, Cecener G, Tezcan G et al (2015) BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer. Gene 556:163–169. https://doi.org/10.1016/j.gene.2014.11.047 PubMedCrossRef

Espinoza I, Pochampally R, Xing F et al (2013) Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther 6:1249–1259. https://doi.org/10.2147/OTT.S36162 PubMedPubMedCentralCrossRef

Felipe Lima J, Nofech-Mozes S, Bayani J, Bartlett JMS (2016) EMT in breast carcinoma—a review. J Clin Med 5:65. https://doi.org/10.3390/jcm5070065 PubMedCentralCrossRef

Ferlay J, Soerjomataram II, Dikshit R et al (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-86. https://doi.org/10.1002/ijc.29210 PubMedCrossRef

Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811. https://doi.org/10.1038/35888 PubMedCrossRef

Fite K, Gomez-Cambronero J (2016) Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 prevents vimentin-triggered, phospholipase D (PLD)-mediated cancer cell invasion. J Biol Chem 291:719–730. https://doi.org/10.1074/jbc.M115.686006 PubMedCrossRef

Fkih M, Privat I, Trimeche M M, et al (2017) miR-10b, miR-26a, miR-146a And miR-153 expression in triple negative vs non triple negative breast cancer: potential biomarkers. Pathol Oncol Res 23:815–827. https://doi.org/10.1007/s12253-017-0188-4 CrossRef

Gasparini P, Cascione L, Fassan M et al (2014) microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5:1174–1184. https://doi.org/10.18632/oncotarget.1682 PubMedPubMedCentralCrossRef

Gomes BC, Martins M, Lopes P, Morujão I, Oliveira M, Araújo A, Rueff J, Rodrigues AS (2016) Prognostic value of microRNA-203a expression in breast cancer. Oncol Rep 36(3):1748–1756. https://doi.org/10.3892/or.2016.4913 PubMedCrossRef

Götte M, Mohr C, Koo C-Y et al (2010) miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29:6569–6580. https://doi.org/10.1038/onc.2010.386 PubMedCrossRef

Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601. https://doi.org/10.1038/ncb1722 PubMedCrossRef

Han M, Wang Y, Liu M et al (2012) MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 103:1058–1064. https://doi.org/10.1111/j.1349-7006.2012.02281.x PubMedCrossRef

Han X, Yan S, Weijie Z et al (2014) Critical role of miR-10b in transforming growth factor-β1-induced epithelial–mesenchymal transition in breast cancer. Cancer Gene Ther 21:60–67. https://doi.org/10.1038/cgt.2013.82 PubMedCrossRef

Hannon GJ, Hammond SM, Bernstein E, Beach D (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404:293–296. https://doi.org/10.1038/35005107 PubMedCrossRef

Hill L, Browne G, Tulchinsky E (2013) ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 132(4):745–754. https://doi.org/10.1002/ijc.27708 PubMedCrossRef

Hollier BG, Tinnirello AA, Werden SJ et al (2013) FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 73:1981–1992. https://doi.org/10.1158/0008-5472.CAN-12-2962 PubMedPubMedCentralCrossRef

Huang Q, Gumireddy K, Schrier M et al (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202–210. https://doi.org/10.1038/ncb1681 PubMedCrossRef

Huang T-H, Wu F, Loeb GB et al (2009) Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem 284:18515–18524. https://doi.org/10.1074/jbc.M109.006676 PubMedPubMedCentralCrossRef

Humphries B, Wang Z, Oom AL et al (2014) MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis 35:2254–2263. https://doi.org/10.1093/carcin/bgu133 PubMedPubMedCentralCrossRef

Huo L, Wang Y, Gong Y et al (2016) MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29:330–346. https://doi.org/10.1038/modpathol.2016.38 PubMedCrossRef

Hutvágner G, McLachlan J, Pasquinelli AE et al (2001) A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science 293:834–838. https://doi.org/10.1126/science.1062961 PubMedCrossRef

Hwang H-W, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94:776–780. https://doi.org/10.1038/sj.bjc.6603023 PubMedPubMedCentralCrossRef

Hwang MS, Yu N, Stinson SY et al (2013) miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One 8:e66502. https://doi.org/10.1371/journal.pone.0066502 PubMedPubMedCentralCrossRef

Jang G-B, Kim J-Y, Cho S-D et al (2015) Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep 5:12465. https://doi.org/10.1038/srep12465 PubMedPubMedCentralCrossRef

Jang MH, Kim HJ, Gwak JM et al (2017) Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol 68:69–78. https://doi.org/10.1016/j.humpath.2017.08.026 PubMedCrossRef

Jurmeister S, Baumann M, Balwierz A et al (2012) MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 32:633–651. https://doi.org/10.1128/MCB.06212-11 PubMedPubMedCentralCrossRef

Kaidi A, Williams AC, Paraskeva C (2007) Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9:210–217. https://doi.org/10.1038/ncb1534 PubMedCrossRef

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428. https://doi.org/10.1172/JCI39104 PubMedPubMedCentralCrossRef

Kolacinska A, Morawiec J, Fendler W et al (2014) Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report. Mol Biol Rep 41:2851–2857. https://doi.org/10.1007/s11033-014-3140-7 PubMedPubMedCentralCrossRef

Kong W, He L, Richards EJ et al (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33:679–689. https://doi.org/10.1038/onc.2012.636 PubMedCrossRef

Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910–14914. https://doi.org/10.1074/jbc.C800074200 PubMedPubMedCentralCrossRef

Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J (2017) Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Human Genet 62:15–24. https://doi.org/10.1038/jhg.2016.89 CrossRef

Lamouille S, Subramanyam D, Blelloch R, Derynck R (2013) Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol 25:200–207. https://doi.org/10.1016/j.ceb.2013.01.008 PubMedPubMedCentralCrossRef

Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196. https://doi.org/10.1038/nrm3758 PubMedPubMedCentralCrossRef

Lee Y, Jeon K, Lee JT et al (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21:4663–4670. https://doi.org/10.1093/emboj/cdf476 PubMedPubMedCentralCrossRef

Lee Y, Ahn C, Han J et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415–419. https://doi.org/10.1038/nature01957 PubMedCrossRef

Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24(Suppl 2):S36–S40. https://doi.org/10.1016/j.breast.2015.07.009 PubMedPubMedCentralCrossRef

Leibovich-Rivkin T, Liubomirski Y, Bernstein B et al (2013) Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures. Neoplasia 15:1330–1346. https://doi.org/10.1593/neo.131688 PubMedPubMedCentralCrossRef

Liang Y, Yang W, Zhu Y, Yuan Y (2016) Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies. Springerplus 5(1):1538. https://doi.org/10.1186/s40064-016-3225-y PubMedPubMedCentralCrossRef

Lim S, Becker A, Zimmer A et al (2013) SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One 8:e66558. https://doi.org/10.1371/journal.pone.0066558 PubMedPubMedCentralCrossRef

Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15:321–333. https://doi.org/10.1038/nrc3932 PubMedPubMedCentralCrossRef

Liu P, Tang H, Chen B et al (2015) MiR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett 357:384–392. https://doi.org/10.1016/j.canlet.2014.11.050 PubMedCrossRef

Liu Y, Zhang Y, Li Q et al (2017) MiRNAs predict the prognosis of patients with triple negative breast cancer: a meta-analysis. PLoS One 12:e0170088. https://doi.org/10.1371/journal.pone.0170088 PubMedPubMedCentralCrossRef

López-Novoa JM, Nieto, MA (2009) Inflammation and EMT: an alliance towards organ fibrosis and cancer progression Introduction—EMT in cancer and fibrosis. EMBO Mol Med 303–314. https://doi.org/10.1002/emmm.200900043

Lu Z, Liu M, Stribinskis V et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27:4373–4379. https://doi.org/10.1038/onc.2008.72 PubMedCrossRef

Lu J, Ye X, Fan F et al (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of jagged-1. Cancer Cell 23:171–185. https://doi.org/10.1016/j.ccr.2012.12.021 PubMedPubMedCentralCrossRef

Lü L, Mao X, Shi P et al (2017) MicroRNAs in the prognosis of triple-negative breast cancer. Med (United States) 96:e7085. https://doi.org/10.1097/MD.0000000000007085 CrossRef

Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688. https://doi.org/10.1038/nature06174 PubMedCrossRef

Ma L, Young J, Prabhala H et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12:247–256. https://doi.org/10.1038/ncb2024 PubMedPubMedCentralCrossRef

MacKenzie TA, Schwartz GN, Calderone HM et al (2014) Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol 184:3217–3225. https://doi.org/10.1016/J.AJPATH.2014.08.020 PubMedPubMedCentralCrossRef

Madhavan D, Cuk K, Burwinkel B, Yang R (2013) Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 4:116. https://doi.org/10.3389/fgene.2013.00116 PubMedPubMedCentralCrossRef

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205 PubMedCrossRef

Martinez J, Patkaniowska A, Urlaub H et al (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563–574. https://doi.org/10.1016/S0092-8674(02)00908-X PubMedCrossRef

Massagué J (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13:616–630. https://doi.org/10.1038/nrm3434 PubMedPubMedCentralCrossRef

Mattos-Arruda L, De Bottai G, Nuciforo PG et al (2015) MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 6:37269–37280. https://doi.org/10.18632/oncotarget.5495 PubMedPubMedCentralCrossRef

Medimegh I, Omrane I, Privat M et al (2014) MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. PLoS One 9:e111877. https://doi.org/10.1371/journal.pone.0111877 PubMedPubMedCentralCrossRef

Mekala JR, Naushad SM, Ponnusamy L et al (2018) Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. Gene 641:248–258. https://doi.org/10.1016/J.GENE.2017.10.018 PubMedCrossRef

Nassirpour R, Mehta PP, Baxi SM, Yin M-J (2013) miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One 8:e62170. https://doi.org/10.1371/journal.pone.0062170 PubMedPubMedCentralCrossRef

Niehrs C (2012) The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13:767–779. https://doi.org/10.1038/nrm3470 PubMedCrossRef

Olivieri F, Rippo MR, Monsurrò V et al (2013) MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev 12:1056–1068. https://doi.org/10.1016/j.arr.2013.05.001 PubMedCrossRef

Ouyang M, Li Y, Ye S et al (2014) MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 9:e96228. https://doi.org/10.1371/journal.pone.0096228 PubMedPubMedCentralCrossRef

Pareja F, Geyer FC, Marchiò C et al (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. Breast Cancer 2:16036. https://doi.org/10.1038/npjbcancer.2016.36 PubMedCrossRef

Paszek S, Gabło N, Barnaś E et al (2017) Dysregulation of microRNAs in triple-negative breast cancer. Ginekol Pol 88:530–536. https://doi.org/10.5603/GP.a2017.0097 PubMedCrossRef

Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han H-D, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee J-S, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo A-M, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK (2013) Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4:2427. https://doi.org/10.1038/ncomms3427 PubMedPubMedCentralCrossRef

Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093 PubMedCrossRef

Piovan C, Palmieri D, Di Leva G et al (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6:458–472. https://doi.org/10.1016/j.molonc.2012.03.003 PubMedPubMedCentralCrossRef

Polyak K (2007) Science in medicine Breast cancer: origins and evolution. Cell 117:3155–3163. https://doi.org/10.1172/JCI33295.group CrossRef

Qi L, Bart J, Tan LP et al (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9:163. https://doi.org/10.1186/1471-2407-9-163 PubMedPubMedCentralCrossRef

Radojicic J, Zaravinos A, Vrekoussis T et al (2011) MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10:507–517. https://doi.org/10.4161/cc.10.3.14754 PubMedCrossRef

Rhodes LV, Martin EC, Segar HC et al (2015) Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget 6:16638–16652. https://doi.org/10.18632/oncotarget.3184 PubMedPubMedCentralCrossRef

Ricciardi M, Zanotto M, Malpeli G et al (2015) Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer 112:1067–1075. https://doi.org/10.1038/bjc.2015.29 PubMedPubMedCentralCrossRef

Sachdeva M, Mo Y-Y (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70:378–387. https://doi.org/10.1158/0008-5472.CAN-09-2021 PubMedCrossRef

Sahlberg KK, Bottai G, Naume B et al (2015) A serum MicroRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 21:1207–1214. https://doi.org/10.1158/1078-0432.CCR-14-2011 CrossRef

Sahlgren C, Gustafsson MV, Jin S et al (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci 105:6392–6397. https://doi.org/10.1073/pnas.0802047105 PubMedCrossRef

Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22:396–403. https://doi.org/10.1016/j.semcancer.2012.04.001 PubMedCrossRef

Sempere LF, Christensen M, Silahtaroglu A et al (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67:11612–11620. https://doi.org/10.1158/0008-5472.CAN-07-5019 PubMedCrossRef

Sethi S, Sarkar FH, Ahmed Q et al (2011) Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 4:222–226. https://doi.org/10.1593/tlo.10244 PubMedPubMedCentralCrossRef

Seton-Rogers S (2016) Epithelial-mesenchymal transition: untangling EMT’s functions. Nat Rev Cancer 16:1. https://doi.org/10.1038/nrc.2015.6 PubMedCrossRef

Shen S, Sun Q, Liang Z et al (2014) A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 9:e100664. https://doi.org/10.1371/journal.pone.0100664 PubMedPubMedCentralCrossRef

Shirakihara T, Horiguchi K, Miyazawa K et al (2011) TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 30:783–795. https://doi.org/10.1038/emboj.2010.351 PubMedPubMedCentralCrossRef

Shivdasani RA (2006) MicroRNAs: regulators of gene expression and cell differentiation. Blood 108:3646–3653. https://doi.org/10.1182/blood-2006-01-030015 PubMedPubMedCentralCrossRef

Shostak K, Chariot A (2011) NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 13:214. https://doi.org/10.1186/bcr2886 PubMedPubMedCentralCrossRef

Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751. https://doi.org/10.1038/onc.2010.215 PubMedPubMedCentralCrossRef

Stinson S, Lackner MR, Adai AT et al (2011) miR-221/222 targeting of trichorh inophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4(186):pt5. https://doi.org/10.1126/scisignal.2002258 PubMedCrossRef

Tao Z, Shi A, Lu C et al (2015) Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–338. https://doi.org/10.1007/s12013-014-0459-6 PubMedCrossRef

Thakur S, Grover RK, Gupta S et al (2016) Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer. PLoS One 11:e0158946. https://doi.org/10.1371/journal.pone.0158946 PubMedPubMedCentralCrossRef

Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890. https://doi.org/10.1016/j.cell.2009.11.007 PubMedCrossRef

Wang Y, Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30:603–611. https://doi.org/10.5732/cjc.011.10226 PubMedPubMedCentralCrossRef

Wang J, Zhao H, Tang D et al (2013) Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother Radiopharm 28:283–288. https://doi.org/10.1089/cbr.2012.1293 PubMedPubMedCentralCrossRef

Wang J, Tsouko E, Jonsson P et al (2014) miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. Mol Oncol 8:1690–1702. https://doi.org/10.1016/j.molonc.2014.07.006 PubMedPubMedCentralCrossRef

Wang S-S, Jiang J, Liang X-H, Tang Y-L (2015) Links between cancer stem cells and epithelial-mesenchymal transition. Onco Targets Ther 8:2973–2980. https://doi.org/10.2147/OTT.S91863 PubMedPubMedCentralCrossRef

Weiss A, Attisano L (2013) The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol 2:47–63. https://doi.org/10.1002/wdev.86 PubMedCrossRef

Wellner U, Schubert J, Burk UC et al (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495. https://doi.org/10.1038/ncb1998 PubMedCrossRef

Wu Y, Deng J, Rychahou PG et al (2009) Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416–428. https://doi.org/10.1016/j.ccr.2009.03.016 PubMedPubMedCentralCrossRef

Yamamoto M, Taguchi Y, Ito-Kureha T et al (2013) NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 4:2299. https://doi.org/10.1038/ncomms3299 PubMedCrossRef

Yang J, Zhang J, Chen J, Xu Y, Song N-H, Yin C-J, Zhang L (2014) Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One 9(1):e87606. https://doi.org/10.1371/journal.pone.0087606 PubMedPubMedCentralCrossRef

Yook JI, Li X-Y, Ota I et al (2006) A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 8:1398–1406. https://doi.org/10.1038/ncb1508 PubMedCrossRef

Yuan T, Wu Y, Zhou BP (2012) Tumor inflammatory microenvironment in EMT and metastasis. Tumor Microenviron Myelomonocyt Cells. https://doi.org/10.5772/32219 CrossRef

Zaravinos A, Apostolos (2015) The regulatory role of MicroRNAs in EMT and cancer. J Oncol 2015:865816. https://doi.org/10.1155/2015/865816 PubMedPubMedCentralCrossRef

Zhao S, Han J, Zheng L et al (2015) MicroRNA-203 regulates growth and metastasis of breast cancer. Cell Physiol Biochem 37:35–42. https://doi.org/10.1159/000430331 PubMedCrossRef

Zhu H, Dai M, Chen X et al (2017) Integrated analysis of the potential roles of miRNA-mRNA networks in triple negative breast cancer. Mol Med Rep 16:1139–1146. https://doi.org/10.3892/mmr.2017.6750 PubMedPubMedCentralCrossRef

Title: MicroRNAs in regulation of triple-negative breast cancer progression
Authors: Dominika Piasecka
Marcin Braun
Radzislaw Kordek
Rafal Sadej
Hanna Romanska
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2689-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2018

Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma

Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations

Vaginal brachytherapy for endometrial cancer

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage